Invega Approved as the First and Only Treatment for Schizoaffective Disorder

Invega Approved as the First and Only Treatment for Schizoaffective Disorder
August 6, 2009
TITUSVILLE, N.J., July 31 /PRNewswire/ -- The U.S. Food and Drug
Administration (FDA) today approved the first and only antipsychotic
for the acute treatment of schizoaffective disorder. Invega
(paliperidone) extended-release tablets were approved for the acute
treatment of schizoaffective disorder either as monotherapy or
adjunctive therapy to mood stabilizers and/or antidepressants. Invega
was approved in 2006 for the treatment of schizophrenia.